Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Omarigliptin (Phase A) → Omarigliptin (Phase B); Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin, Drug: Matching placebo to glimepiride, Drug: Insulin glargine, Drug: Metformin | Arm Label: Placebo to omarigliptin (Phase A) → Glimepiride (Phase B); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to omarigliptin, Drug: Glimepiride, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B) | Intervention Type: DRUG; Name: Matching placebo to omarigliptin; Assigned to Arm(s): Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Matching placebo to glimepiride; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B) | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B), Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B), Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)
D: Arm Label: Omarigliptin; Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin, Drug: Glimepiride Placebo, Drug: Metformin, Drug: Insulin Glargine | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to Omarigliptin, Drug: Glimepiride, Drug: Metformin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Placebo to Omarigliptin; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride Placebo; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glimepiride, Omarigliptin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Glimepiride, Omarigliptin

Answer: B